Circulating AIM prevents hepatocellular carcinoma through complement activation

Cell Reports

Volumn 9, Issue 1, 2014, Pages 61-74

  Maehara, Natsumi ^a   Arai, Satoko ^a   Mori, Mayumi ^a   Iwamura, Yoshihiro ^a,g   Kurokawa, Jun ^a,h   Kai, Toshihiro ^a,g   Kusunoki, Shunsuke ^a   Taniguchi, Kaori ^a   Ikeda, Kazutaka ^b   Ohara, Osamu ^c   Yamamura, Ken ichi ^d   Miyazaki, Toru ^a,e,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c KAZUSA DNA RESEARCH INSTITUTE   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^h ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DIETHYLNITROSAMINE; PROTEIN AIM; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CD5L PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CELL SURFACE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; IMMUNOREGULATION; LIPID DIET; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; C57BL MOUSE; EXPERIMENTAL LIVER NEOPLASM; IMMUNOLOGY; RISK FACTOR; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; COMPLEMENT ACTIVATION; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 84908011887     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.08.058     Document Type: Article

References (60)

1. Angulo P. Nonalcoholic fatty liver disease. N.Engl. J. Med. 2002, 346:1221-1231.
2. Arai S., Shelton J.M., Chen M., Bradley M.N., Castrillo A., Bookout A.L., Mak P.A., Edwards P.A., Mangelsdorf D.J., Tontonoz P., Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005, 1:201-213.
3. Arai S., Maehara N., Iwamura Y., Honda S., Nakashima K., Kai T., Ogishi M., Morita K., Kurokawa J., Mori M., et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep 2013, 3:1187-1198.
4. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
5. Bamberger M., Santos A.M., Gonçalves C.M., Oliveira M.I., James J.R., Moreira A., Lozano F., Davis S.J., Carmo A.M. A new pathway of CD5 glycoprotein-mediated Tcell inhibition dependent on inhibitory phosphorylation of Fyn kinase. J.Biol. Chem. 2011, 286:30324-30336.
6. Bao Y.X., Cao Q., Yang Y., Mao R., Xiao L., Zhang H., Zhao H.R., Wen H. Expression and prognostic significance of golgiglycoprotein73 (GP73) with epithelial-mesenchymal transition (EMT) related molecules in hepatocellular carcinoma (HCC). Diagn. Pathol. 2013, 8:197.
7. Blonski W., Kotlyar D.S., Forde K.A. Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 2010, 16:3603-3615.
8. Bosch F.X., Ribes J., Cléries R., Díaz M. Epidemiology of hepatocellular carcinoma. Clin. Liver Dis. 2005, 9:191-211. v.
9. Braun L., Mead J.E., Panzica M., Mikumo R., Bell G.I., Fausto N. Transforming growth factor beta mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc. Natl. Acad. Sci. USA 1988, 85:1539-1543.
10. Browning J.D., Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J.Clin. Invest. 2004, 114:147-152.
11. Chagas A.L., Kikuchi L.O., Oliveira C.P., Vezozzo D.C., Mello E.S., Oliveira A.C., Cella L.C., Herman P., Bachella T., Caldwell S.H., et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?. Braz. J. Med. Biol. Res. 2009, 42:958-962.
12. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., Caviglia J.M., Khiabanian H., Adeyemi A., Bataller R., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
13. Day C.P., Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J.Gastroenterol. Hepatol. 2002, 17(Suppl 3):S377-S384.
14. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
15. Ertle J., Dechêne A., Sowa J.P., Penndorf V., Herzer K., Kaiser G., Schlaak J.F., Gerken G., Syn W.K., Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 2011, 128:2436-2443.
16. Fan Z., van de Rijn M., Montgomery K., Rouse R.V. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod. Pathol. 2003, 16:137-144.
17. Fang C.M., Xu Y.H. Down-regulated expression of atypical PKC-binding domain deleted asip isoforms in human hepatocellular carcinomas. Cell Res. 2001, 11:223-229.
18. Fong C.W., Chua M.S., McKie A.B., Ling S.H., Mason V., Li R., Yusoff P., Lo T.L., Leung H.Y., So S.K., Guy G.R. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006, 66:2048-2058.
19. Fredrikson G.N., Truedsson L., Sjöholm A.G. New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence. J.Immunol. Methods 1993, 166:263-270.
20. Gilleron J., Carette D., Fiorini C., Dompierre J., Macia E., Denizot J.P., Segretain D., Pointis G. The large GTPase dynamin2: a new player in connexin 43 gap junction endocytosis, recycling and degradation. Int. J. Biochem. Cell Biol. 2011, 43:1208-1217.
21. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 2003, 98:2042-2047.
22. He G., Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011, 21:159-168.
23. He G., Dhar D., Nakagawa H., Font-Burgada J., Ogata H., Jiang Y., Shalapour S., Seki E., Yost S.E., Jepsen K., et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013, 155:384-396.
24. Hill-Baskin A.E., Markiewski M.M., Buchner D.A., Shao H., DeSantis D., Hsiao G., Subramaniam S., Berger N.A., Croniger C., Lambris J.D., Nadeau J.H. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum. Mol. Genet. 2009, 18:2975-2988.
25. Hörl S., Bánki Z., Huber G., Ejaz A., Windisch D., Muellauer B., Willenbacher E., Steurer M., Stoiber H. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity. Leukemia 2013, 27:2200-2208.
26. Huang M., Liu G. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett. 1999, 135:97-105.
27. Hytiroglou P., Park Y.N., Krinsky G., Theise N.D. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol. Clin. North Am. 2007, 36:867-887. vii.
28. Imai M., Ohta R., Okada N., Tomlinson S. Inhibition of a complement regulator invivo enhances antibody therapy in a model of mammary adenocarcinoma. Int. J. Cancer 2004, 110:875-881.
29. Iwamura Y., Mori M., Nakashima K., Mikami T., Murayama K., Arai S., Miyazaki T. Apoptosis inhibitor of macrophage (AIM) diminishes lipid droplet-coating proteins leading to lipolysis in adipocytes. Biochem. Biophys. Res. Commun. 2012, 422:476-481.
30. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
31. Kato A., Miyazaki M., Ambiru S., Yoshitomi H., Ito H., Nakagawa K., Shimizu H., Yokosuka O., Nakajima N. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J.Surg. Oncol. 2001, 78:110-115.
32. Kawada N., Imanaka K., Kawaguchi T., Tamai C., Ishihara R., Matsunaga T., Gotoh K., Yamada T., Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J.Gastroenterol. 2009, 44:1190-1194.
33. Kelley D.S., Nelson G.J., Hunt J.E. Effect of prior nutritional status on the activity of lipogenic enzymes in primary monolayer cultures of rat hepatocytes. Biochem. J. 1986, 235:87-90.
34. Kojima A., Iwata K., Seya T., Matsumoto M., Ariga H., Atkinson J.P., Nagasawa S. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J.Immunol. 1993, 151:1519-1527.
35. Kuo M.T., Zhao J.Y., Teeter L.D., Ikeguchi M., Chisari F.V. Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell Growth Differ. 1992, 3:531-540.
36. Kurokawa J., Arai S., Nakashima K., Nagano H., Nishijima A., Miyata K., Ose R., Mori M., Kubota N., Kadowaki T., et al. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab. 2010, 11:479-492.
37. Kurokawa J., Nagano H., Ohara O., Kubota N., Kadowaki T., Arai S., Miyazaki T. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc. Natl. Acad. Sci. USA 2011, 108:12072-12077.
38. Marrero J.A., Romano P.R., Nikolaeva O., Steel L., Mehta A., Fimmel C.J., Comunale M.A., D'Amelio A., Lok A.S., Block T.M. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J.Hepatol. 2005, 43:1007-1012.
39. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J.Exp. Med. 1984, 160:1558-1578.
40. Miwa T., Song W.C. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int. Immunopharmacol. 2001, 1:445-459.
41. Miyazaki T., Hirokami Y., Matsuhashi N., Takatsuka H., Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J.Exp. Med. 1999, 189:413-422.
42. Mosesson Y., Mills G.B., Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer 2008, 8:835-850.
43. Müller-Eberhard H.J. The membrane attack complex of complement. Annu. Rev. Immunol. 1986, 4:503-528.
44. Nordenstedt H., White D.L., El-Serag H.B. The changing pattern of epidemiology in hepatocellular carcinoma. Dig. Liver Dis. 2010, 42(Suppl 3):S206-S214.
45. Ohta R., Kondor N., Dohi N., Tomlinson S., Imai M., Holers V.M., Okada H., Okada N. Mouse complement receptor-related gene y/p65-neutralized tumor vaccine induces antitumor activity invivo. J.Immunol. 2004, 173:205-213.
46. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V., Bedossa P., Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
47. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
48. Polo S., Pece S., Di Fiore P.P. Endocytosis and cancer. Curr. Opin. Cell Biol. 2004, 16:156-161.
49. Powell E.E., Cooksley W.G., Hanson R., Searle J., Halliday J.W., Powell L.W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990, 11:74-80.
50. Sargin B., Choudhary C., Crosetto N., Schmidt M.H., Grundler R., Rensinghoff M., Thiessen C., Tickenbrock L., Schwäble J., Brandts C., et al. Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007, 110:1004-1012.
51. Sarrias M.R., Roselló S., Sánchez-Barbero F., Sierra J.M., Vila J., Yélamos J., Vives J., Casals C., Lozano F. A role for human Sp alpha as a pattern recognition receptor. J.Biol. Chem. 2005, 280:35391-35398.
52. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjöholm A.G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J.Immunol. Methods 2005, 296:187-198.
53. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37, 56-62. Polo, S., Pece, S., and Di Fiore, P.P. (2004). Endocytosis and cancer. Curr. Opin. Cell Biol. 2002, 16:156-161.
54. So C.W., Lin M., Ayton P.M., Chen E.H., Cleary M.L. Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell 2003, 4:99-110.
55. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
56. Takuma Y., Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J. Gastroenterol. 2010, 16:1436-1441.
57. Tissot J.D., Sanchez J.C., Vuadens F., Scherl A., Schifferli J.A., Hochstrasser D.F., Schneider P., Duchosal M.A. IgM are associated to Sp alpha (CD5 antigen-like). Electrophoresis 2002, 23:1203-1206.
58. Torres D.M., Harrison S.A. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin. Liver Dis. 2012, 32:30-38.
59. Verna L., Whysner J., Williams G.M. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol. Ther. 1996, 71:57-81.
60. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., Iwakura Y., Oshima K., Morita H., Hattori M., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.